Pacira Pharmaceuticals Company Profile (NASDAQ:PCRX)

Pacira Pharmaceuticals trades on the NASDAQ under the ticker symbol "PCRX."

Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) posted its quarterly earnings data on Thursday, May, 4th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.04. The business earned $69.30 million during the quarter, compared to analysts' expectations of $70.30 million. Pacira Pharmaceuticals had a negative net margin of 19.26% and a negative return on equity of 7.71%. The business's revenue was up 5.8% on a year-over-year basis. During the same period last year, the firm posted $0.15 earnings per share. View Pacira Pharmaceuticals' Earnings History.

14 brokerages have issued 1-year target prices for Pacira Pharmaceuticals' stock. Their predictions range from $36.00 to $87.00. On average, they anticipate Pacira Pharmaceuticals' stock price to reach $56.00 in the next twelve months. View Analyst Ratings for Pacira Pharmaceuticals.

Here are some recent quotes from research analysts about Pacira Pharmaceuticals stock:

• 1. Cowen and Company analysts commented, "Nerve block data for Exparel is anticipated within the next month, and our consultants." (7/14/2017)
• 2. According to Zacks Investment Research, "The company’s efforts to expand Exparel's label to boost sales in oral surgery and chronic pain are encouraging. The company reported positive topline results for Exparel from its phase IV study in total knee arthroplasty (TKA). The company also collaborated with DePuy Synthes which is expected to significantly expand use of Exparel across a broad range of surgical procedures. Pacira is looking to expand Exparel's label in the animal health market as well. Its share price has underperformed the broader industry in the past one year. However, Pacira’s sole dependence on Exparel for top-line growth is concerning. We are also concerned about the lack of other late-stage candidates in the company’s pipeline. Estimate movement has been mixed lately ahead of the Q1 earnings results. Pacira has a positive record of earnings surprises in recent quarters." (5/2/2017)
• 3. Mizuho analysts commented, "We continue to like PCRX for the 2017 potential catalyst flow (ahead of the nerve block data), growth opportunities from increased DePuy Synthes (DPS) orthopedic promotion, and a reasonable takeout thesis. We updated our share count and interest expense following the recent convertible debt refinancing, and included the latest Feb data from Symphony. While we are comfortable with the growth rates we estimate for the 20 mL vial, we need to monitor our expectations for the smaller 10 mL vial that launched this year and is not yet reported by Symphony. Our estimates came down slightly due to lowered expectations on this 10 mL vial and we lower our PT to $54 from $59 due to additional share count dilution and increase in net debt." (3/23/2017)

Some companies that are related to Pacira Pharmaceuticals include Opko Health (OPK), Hikma Pharmaceuticals Plc (HIK), BTG plc (BTG), Amicus Therapeutics (FOLD), Horizon Pharma PLC (HZNP), Theravance Biopharma (TBPH), Cambrex Corporation (CBM), Corcept Therapeutics Incorporated (CORT), Innoviva (INVA), Impax Laboratories (IPXL), Amphastar Pharmaceuticals (AMPH), Lannett Co (LCI), AMAG Pharmaceuticals (AMAG), SciClone Pharmaceuticals (SCLN), Aceto Corporation (ACET), Teligent (TLGT), Collegium Pharmaceutical (COLL) and Aquinox Pharmaceuticals (AQXP).

Pacira Pharmaceuticals' management team includes the folowing people:

• David M. Stack, Chairman of the Board, Chief Executive Officer
• Charles A. Reinhart III, Chief Financial Officer
• Scott N. Braunstein M.D., Senior Vice President - Strategy and Corporate Development
• James B. Jones M.D., Senior Vice President, Chief Medical Officer
• Kristen Marie Williams, Chief Administrative Officer, General Counsel, Secretary
• Robert J. Weiland, Chief Commercial Officer
• Mark Froimson, Director
• Gary Pace Ph.D., Director
• Laura A. Brege, Independent Director
• Yvonne L. Greenstreet M.D., Independent Director

Pacira Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include Peregrine Capital Management LLC (0.89%), Bank of Montreal Can (0.08%), Mizuho Securities USA LLC (0.02%), Malaga Cove Capital LLC (0.02%), Fisher Asset Management LLC (0.02%) and US Bancorp DE (0.01%). Company insiders that own Pacira Pharmaceuticals stock include David M Stack, James B Jones, James S Scibetta, John P Phd Longenecker, Kristen Marie Williams, Lauren Bullaro Riker, Mark A Kronenfeld, Paul J Hastings and Scott Braunstein. View Institutional Ownership Trends for Pacira Pharmaceuticals.

Pacira Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Bank of Montreal Can, US Bancorp DE and Peregrine Capital Management LLC. Company insiders that have sold Pacira Pharmaceuticals stock in the last year include David M Stack, James S Scibetta, Kristen Marie Williams, Lauren Bullaro Riker and Scott Braunstein. View Insider Buying and Selling for Pacira Pharmaceuticals.

Pacira Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Malaga Cove Capital LLC. Company insiders that have bought Pacira Pharmaceuticals stock in the last two years include James B Jones, James S Scibetta, John P Phd Longenecker and Scott Braunstein. View Insider Buying and Selling for Pacira Pharmaceuticals.

Shares of Pacira Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Pacira Pharmaceuticals stock can currently be purchased for approximately $48.70.